{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:14:31Z","timestamp":1760919271739,"version":"build-2065373602"},"reference-count":151,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cld.2025.06.012","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:18:58Z","timestamp":1755083938000},"page":"595-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Approaches to Alcohol-Associated Hepatitis"],"prefix":"10.1016","volume":"29","author":[{"given":"Rohit Sunilrao","family":"Wagh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saggere Muralikrishna","family":"Shasthry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2025.06.012_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL clinical practice guidelines: management of alcohol-related liver disease","volume":"69","author":"Thursz","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions, and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.012_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/liv.15221","article-title":"Management of alcohol-related liver disease: the French association for the study of the liver and the French alcohol society clinical guidelines","volume":"42","author":"Louvet","year":"2022","journal-title":"Liver Int"},{"issue":"15","key":"10.1016\/j.cld.2025.06.012_bib4","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.3748\/wjg.v22.i15.3892","article-title":"New treatment options for alcoholic hepatitis","volume":"22","author":"Shasthry","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2025.06.012_bib5","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib6","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMra2207599","article-title":"Alcohol-associated hepatitis","volume":"387","author":"Bataller","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2025.06.012_bib7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2021.7683","article-title":"Diagnosis and treatment of alcohol-associated liver disease: a review","volume":"326","author":"Singal","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2025.06.012_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/apt.16969","article-title":"Review article: current and emerging therapies for acute alcohol-associated hepatitis","volume":"56","author":"Rattan","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2025.06.012_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update","volume":"13","author":"Sarin","year":"2019","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.cld.2025.06.012_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/gut.29.1.101","article-title":"Young v adult cirrhotics: a prospective, comparative analysis of the clinical profile, natural course, and survival","volume":"29","author":"Sarin","year":"1988","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2025.06.012_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.14309\/ajg.0000000000000411","article-title":"Increasing burden of acute-on-chronic liver failure among alcohol-associated liver disease in the young population in the United States","volume":"115","author":"Singal","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.06.012_bib12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/apt.16461","article-title":"Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics","volume":"54","author":"Singal","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2025.06.012_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.14309\/ajg.0000000000001007","article-title":"Excess mortality after liver transplantation in young women with alcohol-associated liver disease","volume":"116","author":"Lee","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.012_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.012_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/hep.20503","article-title":"MELD accurately predicts mortality in patients with alcoholic hepatitis","volume":"41","author":"Dunn","year":"2005","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2025.06.012_bib16","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1111\/j.1572-0241.2008.02104.x","article-title":"A new scoring system for prognostic stratification of patients with alcoholic hepatitis","volume":"103","author":"Dominguez","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.cld.2025.06.012_bib17","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/gut.2004.050781","article-title":"Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score","volume":"54","author":"Forrest","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.06.012_bib18","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cld.2025.06.012_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","article-title":"Inflammatory pathways in alcoholic steatohepatitis","volume":"70","author":"Gao","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.06.012_bib21","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2023.05.017","article-title":"The role of neutrophils in alcohol-related hepatitis","volume":"79","author":"Khan","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jhep.2022.08.029","article-title":"Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcohol-associated hepatitis","volume":"78","author":"Cho","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib23","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/hep.29645","article-title":"Pyroptosis by caspase11\/4-gasdermin- D pathway in alcoholic hepatitis in mice and patients","volume":"67","author":"Khanova","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib24","first-page":"342","article-title":"Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis","volume":"70","author":"Takeuchi","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.06.012_bib25","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.30228","article-title":"Effects of endotoxin on type 3 inositol 1,4,5-trisphosphate receptor in human cholangiocytes","volume":"69","author":"Franca","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jhep.2018.03.031","article-title":"Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis","volume":"69","author":"Brandl","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.06.012_bib27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/apt.15335","article-title":"STOPAH NLR Group. Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis","volume":"50","author":"Forrest","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"supplement 3","key":"10.1016\/j.cld.2025.06.012_bib28","article-title":"p-48 comparison of the ALBI model (albumin\/bilirubin index) with established scales as predictor of response to steroid treatment in patients with severe alcoholic hepatitis","volume":"29","author":"Nava","year":"2024","journal-title":"Ann Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.06.012_bib29","article-title":"Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality","volume":"6","author":"Pearson","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cld.2025.06.012_bib30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF01296284","article-title":"Relationship between degree of portal hypertension and liver histologic lesions in patients with alcoholic cirrhosis. Effect of acute alcoholic hepatitis on portal hypertension","volume":"32","author":"Poynard","year":"1987","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2025.06.012_bib31","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0168-8278(05)80496-9","article-title":"Splanchnic and systemic hemodynamics in early abstinence and after ethanol administration in non-cirrhotic alcoholic patients","volume":"20","author":"Silva","year":"1994","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1365-2036.2007.03258.x","article-title":"Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis","volume":"25","author":"Rincon","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.012_bib33","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/MEG.0000000000001148","article-title":"A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis","volume":"30","author":"Spahr","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib34","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/j.gastro.2014.01.018","article-title":"A histologic scoring system for prognosis of patients with alcoholic hepatitis","volume":"146","author":"Altamirano","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2025.06.012_bib35","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cgh.2013.08.048","article-title":"The breathprints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis","volume":"12","author":"Hanouneh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.06.012_bib36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.0954-6820.1955.tb18248.x","article-title":"Urinary excretion of trimethylamine and trimethylamine oxide following trimethylamine-administration to normals and to patients with liver disease","volume":"153","author":"Wranne","year":"1955","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.cld.2025.06.012_bib37","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.cgh.2019.11.050","article-title":"Keratin 18 is a diagnostic and prognostic factor for acute alcoholic hepatitis","volume":"18","author":"Vatsalya","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep.29080","article-title":"A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis","volume":"66","author":"Bissonnette","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib39","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.14309\/ajg.0000000000000912","article-title":"In severe alcoholic hepatitis, serum Keratin-18 fragments are diagnostic, prognostic, and theragnostic biomarkers","volume":"115","author":"Atkinson","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2025.06.012_bib40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3727\/105221617X15016197658871","article-title":"Cell death and prognosis of mortality in alcoholic hepatitis patients using plasma keratin-18","volume":"17","author":"Woolbright","year":"2017","journal-title":"Gene Expr"},{"issue":"9","key":"10.1016\/j.cld.2025.06.012_bib41","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1136\/gutjnl-2015-311314","article-title":"Integrative microRNA profiling in alcohol-associated hepatitis reveals a role for microRNA-182 in liver injury and inflammation","volume":"65","author":"Blaya","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.06.012_bib42","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/hep.31994","article-title":"Transcriptomic analysis reveals the MicroRNAs responsible for liver regeneration associated with mortality in alcohol-associated hepatitis","volume":"74","author":"Yang","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib43","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.cgh.2017.11.022","article-title":"Molecular ellipticity of circulating albumin-bilirubin complex associates with mortality in patients with severe alcohol-associated hepatitis","volume":"16","author":"Das","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib44","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0168-8278(20)30658-9","article-title":"Lipidomics profiling reveals a distinct pattern of selective lipid depletion in the circulation and liver tissue in patients with progressive alcohol-associated liver fibrosis: a biopsy-controlled study in 400 people","volume":"73","author":"Thiele","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30870-9","article-title":"Alterations and role of bioactive lipid metabolites (oxylipins) in human and experimental ALD: associations with disease severity","volume":"73","author":"Warner","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30859-X","article-title":"A novel lymphocyte proliferation assay accurately predicts 90-day survival in severe alcohol-associated hepatitis patients","volume":"73","author":"Yates","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib47","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12967-015-0623-9","article-title":"Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcohol-associated hepatitis","volume":"13","author":"Momen-Heravi","year":"2015","journal-title":"J Transl Med"},{"key":"10.1016\/j.cld.2025.06.012_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep10721","article-title":"Biodistribution and function of extracellular miRNA-155 in mice","volume":"5","author":"Bala","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.cld.2025.06.012_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30882-5","article-title":"The development and severity of alcohol-associated hepatitis is associated with decreased intestinal microbiome-derived secondary bile acid isoursodeoxycholic acid","volume":"73","author":"Muthiah","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41586-019-1742-x","article-title":"Bacteriophage targeting of gut bacterium attenuates alcohol-associated liver disease","volume":"575","author":"Duan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.cld.2025.06.012_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30868-0","article-title":"Temporal change in the plasma metabolome profile is indicative of outcome in severe alcohol-associated hepatitis","volume":"73","author":"Maras","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib52","unstructured":"Abstract no. 0038 | Fecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis, AASLD ABSTRACT, 2024."},{"key":"10.1016\/j.cld.2025.06.012_bib53","unstructured":"Abstract no. 3020 | Cardiolipin treatment in hepatocyte specific Ptpmt1-\/- mice is hepatoprotective in an animal model of alcohol-associated hepatitis, AASLD ABSTRACT, 2024."},{"key":"10.1016\/j.cld.2025.06.012_bib54","unstructured":"Abstract no. 3058 | subcutaneous injection of galanin attenuates alcoholic hepatitis and abdominal adipose tissue inflammation induced by ethanol binge in Ob\/Ob mice, AASLD ABSTRACT, 2024."},{"key":"10.1016\/j.cld.2025.06.012_bib55","unstructured":"Abstract no. 3095 | Glp-1 receptor agonism reduces injury, hepatic Cyp2e1 activity and increases antioxidant activity in A mouse model of alcohol-induced acute hepatitis, AASLD ABSTRACT, 2024."},{"key":"10.1016\/j.cld.2025.06.012_bib56","unstructured":"Abstract no. 3107 | Therapeutic inhibition of Bruton\u2019s tyrosine kinase (Btk) acts on both immune cells and hepatocytes to attenuate immune cell activation and steatosis in A mouse model of alcohol-associated hepatitis, AASLD ABSTRACT, 2024."},{"key":"10.1016\/j.cld.2025.06.012_bib57","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2019.12.023","article-title":"Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis, and Maddrey\u2019s discriminant function <32","volume":"72","author":"Degre","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib58","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1002\/hep.29338","article-title":"Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: prediction and impact on long-term survival","volume":"66","author":"Altamirano","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib59","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.29240","article-title":"Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: a prospective study","volume":"66","author":"Louvet","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib60","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/MEG.0b013e32835d83d9","article-title":"Recurrent severe alcoholic hepatitis: clinical characteristics and outcomes","volume":"25","author":"Potts","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib61","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S2468-1253(19)30415-7","article-title":"Outpatient management of alcohol related liver disease","volume":"5","author":"Simonetto","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.06.012_bib62","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000145","article-title":"Management of alcohol use disorder in patients with chronic liver disease","volume":"7","author":"Mellinger","year":"2023","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.cld.2025.06.012_bib63","article-title":"Benzodiazepines for alcohol withdrawal","author":"Amato","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cld.2025.06.012_bib64","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/archinte.164.13.1405","article-title":"Management of alcohol withdrawal delirium. An evidence-based practice guideline","volume":"164","author":"Mayo-Smith","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cld.2025.06.012_bib65","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40263-016-0403-y","article-title":"Diazepam in the treatment of moderate to severe alcohol withdrawal","volume":"31","author":"Weintraub","year":"2017","journal-title":"CNS Drugs"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2025.06.012_bib66","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.jhep.2021.01.025","article-title":"Sarcopenia, and frailty in decompensated cirrhosis","volume":"75","author":"Tandon","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib67","doi-asserted-by":"crossref","first-page":"G241","DOI":"10.1152\/ajpgi.00373.2020","article-title":"Sarcopenia in chronic liver disease: mechanisms and countermeasures","volume":"320","author":"Allen","year":"2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cld.2025.06.012_bib68","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13539-012-0069-3","article-title":"Consilience in sarcopenia of cirrhosis","volume":"3","author":"Dasarathy","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.cld.2025.06.012_bib69","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","article-title":"ESPEN guideline on clinical nutrition in liver disease","volume":"38","author":"Plauth","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.cld.2025.06.012_bib70","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM198412063112302","article-title":"Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone","volume":"311","author":"Charles","year":"1984","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2025.06.012_bib71","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/j.gastro.2015.12.038","article-title":"Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids","volume":"150","author":"Moreno","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2025.06.012_bib72","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jhep.2000.8627","article-title":"Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial","volume":"32","author":"Cabr\u00e9","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib73","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/bmj.299.6709.1202","article-title":"Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver","volume":"299","author":"Swart","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.cld.2025.06.012_bib74","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0168-8278(05)80221-1","article-title":"Nocturnal oral glucose supplementation. The effects on protein metabolism in cirrhotic patients and in healthy controls","volume":"17","author":"Zillikens","year":"1993","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib75","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1440-1746.2011.06951.x","article-title":"Late evening snack: exploiting a period of anabolic opportunity in cirrhosis","volume":"27","author":"Tsien","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib76","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cgh.2015.09.028","article-title":"Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial","volume":"14","author":"Maharshi","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib77","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/hep.22367","article-title":"Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial","volume":"48","author":"Plank","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib78","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11938-017-0132-4","article-title":"Role of zinc in the development\/progression of alcoholic liver disease","volume":"15","author":"McClain","year":"2017","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.012_bib79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.cld.2025.06.012_bib80","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2025.06.012_bib81","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo\u2014a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.012_bib82","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000003416","article-title":"Infections in standard or tapered dose of prednisolone for alcohol-associated hepatitis: a randomized trial (STASH trial)","author":"Kulkarni","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.012_bib83","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3350\/cmh.2020.0196","article-title":"Predictors of steroid non-response and new approaches in severe alcoholic hepatitis","volume":"26","author":"Sarin","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib84","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/hep4.1176","article-title":"Baseline urine metabolic phenotype in patients with severe alcoholic hepatitis and its association with outcome","volume":"2","author":"Maras","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2025.06.012_bib85","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/apt.14564","article-title":"Microvesicles in hepatic and peripheral vein can predict nonresponse to corticosteroid therapy in severe alcoholic hepatitis","volume":"47","author":"Sukriti","year":"2018","journal-title":"Ailment Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.012_bib86","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1038\/s41598-017-07161-4","article-title":"Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness","volume":"7","author":"Sharma","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cld.2025.06.012_bib87","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00428-018-2330-4","article-title":"Histological activity score on baseline liver biopsy can predict non-response to steroids in patients with severe alcoholic hepatitis","volume":"472","author":"Shasthry","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.cld.2025.06.012_bib88","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/hep.28897","article-title":"Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis","volume":"65","author":"Das","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12185-016-2162-4","article-title":"Cellular players of hematopoietic stem cell mobilization in the bone marrow niche","volume":"105","author":"Tay","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cld.2025.06.012_bib90","first-page":"152","article-title":"Infections in severe alcoholic hepatitis","volume":"30","author":"Karakike","year":"2017","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.012_bib91","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/hep.21737","article-title":"Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome","volume":"46","author":"Mookerjee","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib92","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2007.05.018","article-title":"Granulocyte- colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats","volume":"133","author":"Piscaglia","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.012_bib93","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/j.gastro.2011.11.027","article-title":"Granulocyte colony-stimulating factor mobilizes CD34+ cells and improves survival of patients with acute-on-chronic liver failure","volume":"142","author":"Garg","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.012_bib94","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.30516","article-title":"Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial","volume":"70","author":"Shasthry","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.06.012_bib95","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.14309\/ajg.0000000000003038","article-title":"Granulocyte colony-stimulating factor improves prednisolone responsiveness and 90-Day survival in steroid-eligible severe alcohol-associated hepatitis: the GPreAH study a randomized trial","volume":"120","author":"Mishra","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.012_bib96","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/liv.13923","article-title":"Early cirrhosis and a preserved bone marrow niche favour regenerative response to growth factors in decompensated cirrhosis","volume":"39","author":"Anand","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2025.06.012_bib97","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nature07537","article-title":"A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity","volume":"457","author":"Cella","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.cld.2025.06.012_bib98","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00262-012-1241-5","article-title":"Increased intratumoral IL-22-producing CD4(\u00fe) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival","volume":"61","author":"Zhuang","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cld.2025.06.012_bib99","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s12072-020-10082-6","article-title":"Interleukin-22 in alcoholic hepatitis and beyond","volume":"14","author":"Xiang","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2025.06.012_bib100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib101","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/liv.12570","article-title":"The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"35","author":"Barreyro","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2025.06.012_bib102","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cgh.2018.06.012","article-title":"Emricasan improves liver function in patients with cirrhosis and high model for end-stage liver disease scores compared with placebo","volume":"17","author":"Frenette","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib103","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2018.10.026","article-title":"Current trials and novel therapeutic targets for alcoholic hepatitis","volume":"70","author":"Singal","year":"2019","journal-title":"J Hepatol"},{"issue":"Suppl1","key":"10.1016\/j.cld.2025.06.012_bib104","first-page":"8A","article-title":"Selonsertib in combination with prednisolone for the treatment of severe alcoholic hepatitis: a phase 2 randomized controlled trial","volume":"68","author":"Mathurin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib105","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.06.012_bib106","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12072-022-10438-0","article-title":"Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial","volume":"17","author":"Pande","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cld.2025.06.012_bib107","unstructured":"Abstract no. 0013 | FECAL MICROBIOTA THERAPY IS A SAFE AND EFFECTIVE OPTION IN STEROID INELIGIBLE ALCOHOLIC HEPATITIS (FEMTAH TRIAL): A RCT, Rahul Khajuria, Shasthry S M, Shiv Kumar Sarin, AASLD Abstract 2024."},{"issue":"2","key":"10.1016\/j.cld.2025.06.012_bib108","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12072-022-10312-z","article-title":"Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial","volume":"16","author":"Sharma","year":"2022","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.cld.2025.06.012_bib109","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot Study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib110","doi-asserted-by":"crossref","first-page":"goac074","DOI":"10.1093\/gastro\/goac074","article-title":"Clinical outcomes and gut microbiota analysis of severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala","volume":"10","author":"Philips","year":"2022","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"18","key":"10.1016\/j.cld.2025.06.012_bib111","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/jama.2023.4902","article-title":"Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial","volume":"329","author":"Louvet","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cld.2025.06.012_bib112","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.alcohol.2008.08.006","article-title":"Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study","volume":"42","author":"Kirpich","year":"2008","journal-title":"Alcohol"},{"issue":"8","key":"10.1016\/j.cld.2025.06.012_bib113","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.14309\/ajg.0000000000002283","article-title":"The beneficial effects of lactobacillus GG therapy on liver and drinking assessments in patients with moderate alcohol-associated hepatitis","volume":"118","author":"Vatsalya","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.012_bib114","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/hep.31623","article-title":"Phage therapy for alcohol-associated hepatitis","volume":"73","author":"Suh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib115","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2025.06.012_bib116","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1053\/j.gastro.2015.06.006","article-title":"Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis","volume":"149","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"issue":"16","key":"10.1016\/j.cld.2025.06.012_bib117","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.3748\/wjg.v21.i16.4975","article-title":"Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis","volume":"21","author":"Higuera-de la Tijera","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.012_bib118","unstructured":"Efficacy Study of Anakinra Pentoxifylline, and zinc compared to methylprednisolone in severe acute alcoholic hepatitis. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01809132."},{"key":"10.1016\/j.cld.2025.06.012_bib119","unstructured":"Trial of anakinra (plus zinc) or prednisone in patients with severe alcoholic hepatitis. Full text view - clinicaltrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04072822."},{"issue":"5","key":"10.1016\/j.cld.2025.06.012_bib120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cgh.2024.07.025","article-title":"IL-1 signal inhibition in alcohol-related hepatitis: a randomized, Double-Blind, placebo-controlled trial of canakinumab","volume":"23","author":"Vergis","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib121","first-page":"1483A","article-title":"Safety and efficacy of DUR-928: a potential new therapy for acute alcoholic hepatitis","volume":"70","author":"Hassanein","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib122","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1038\/s41467-021-24843-w","article-title":"Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cld.2025.06.012_bib123","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/hep.29676","article-title":"Modulation of the intestinal bile acid\/farnesoid X receptor\/fibroblast growth factor 15 axis improves alcoholic liver disease in mice","volume":"67","author":"Hartmann","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib124","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.012_bib125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2018.05.012","article-title":"Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis","volume":"69","author":"Peeraphatdit","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib126","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2025.06.012_bib127","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.012_bib128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/nure.12089","article-title":"Clinical applications of bovine colostrum therapy: a systematic review","volume":"72","author":"Rathe","year":"2014","journal-title":"Nutr Rev"},{"key":"10.1016\/j.cld.2025.06.012_bib129","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/cc1819","article-title":"Bovine colostrum in oral treatment of enterogenic endotoxaemia in rats","volume":"6","author":"D\u20acohler","year":"2002","journal-title":"Crit Care"},{"key":"10.1016\/j.cld.2025.06.012_bib130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.nut.2018.10.013","article-title":"Effects of early enteral bovine colostrum supplementation on intestinal permeability in critically ill patients: a randomized, double-blind, placebo-controlled study","volume":"60","author":"Eslamian","year":"2019","journal-title":"Nutrition"},{"key":"10.1016\/j.cld.2025.06.012_bib131","unstructured":"(NCT02265328). Available at: https:\/\/clinicaltrials.gov."},{"key":"10.1016\/j.cld.2025.06.012_bib132","unstructured":"(NCT01968382). Available at: https:\/\/clinicaltrials.gov."},{"key":"10.1016\/j.cld.2025.06.012_bib133","unstructured":"(NCT02473341). Available at: https:\/\/clinicaltrials.gov."},{"issue":"5","key":"10.1016\/j.cld.2025.06.012_bib134","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2025.06.012_bib135","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2008.10.024","article-title":"Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial","volume":"50","author":"Sharma","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib136","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/MEG.0b013e328332a360","article-title":"Granulocytapheresis in the treatment of severe alcoholic hepatitis: a case series","volume":"22","author":"Morris","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.012_bib137","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10620-013-2871-y","article-title":"Granulocytapheresis for the treatment of severe alcoholic hepatitis: a case series and literature review","volume":"59","author":"Kamimura","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2025.06.012_bib138","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2011.12.056","article-title":"Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure","volume":"142","author":"Kribben","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.012_bib139","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/S0168-8278(18)30308-8","article-title":"Therapeutic plasma-exchange improves systemic inflammation and survival in patients with acute on chronic liver failure","volume":"68","author":"Maiwall","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.012_bib140","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s12664-024-01569-3","article-title":"Centrifugal technique of plasma exchange and low-dose steroid to treat very severe alcoholic hepatitis patients: a retrospective analysis","volume":"44","author":"Kumar","year":"2025","journal-title":"Indian J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2025.06.012_bib141","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jceh.2021.07.010","article-title":"Low volume plasma exchange and low dose steroid improve survival in patients with alcohol-related acute on chronic liver failure and severe alcoholic hepatitis - preliminary experience","volume":"12","author":"Kumar","year":"2022","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.06.012_bib142","first-page":"240","article-title":"Survival and quality of life after liver transplantation for acute alcoholic hepatitis A","volume":"3","author":"Shakil","year":"1997","journal-title":"Liver Transplant Surg"},{"issue":"4","key":"10.1016\/j.cld.2025.06.012_bib143","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.transproceed.2009.03.092","article-title":"Alcohol abstinence and orthotopic liver transplantation in alcoholic liver cirrhosis","volume":"41","author":"Immordino","year":"2009","journal-title":"Transplant Proc"},{"issue":"19","key":"10.1016\/j.cld.2025.06.012_bib144","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1105703","article-title":"Early liver transplantation for severe alcoholic hepatitis","volume":"365","author":"Mathurin","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.cld.2025.06.012_bib145","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/lt.24208","article-title":"Liver transplantation for alcoholic hepatitis: a survey of liver transplant centers","volume":"21","author":"Hasanin","year":"2015","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.cld.2025.06.012_bib146","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.gastro.2018.04.009","article-title":"Outcomes of early liver transplantation for patients with severe alcoholic hepatitis","volume":"155","author":"Lee","year":"2018","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2025.06.012_bib147","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/lt.25285","article-title":"Survey of liver transplantation practices for severe acute alcoholic hepatitis","volume":"24","author":"Bangaru","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cld.2025.06.012_bib148","doi-asserted-by":"crossref","first-page":"645","DOI":"10.15288\/jsa.1993.54.645","article-title":"Descriptive and predictive validity of a high-risk alcoholism relapse model","volume":"54","author":"Yates","year":"1993","journal-title":"J Stud Alcohol"},{"key":"10.1016\/j.cld.2025.06.012_bib149","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/archinte.167.11.1183","article-title":"A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years","volume":"167","author":"De Gottardi","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cld.2025.06.012_bib150","first-page":"1198","article-title":"Use of a high-risk alcohol relapse scale in evaluating liver transplant candidates","volume":"24","author":"DiMartini","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.cld.2025.06.012_bib151","doi-asserted-by":"crossref","first-page":"310","DOI":"10.7182\/pit2013604","article-title":"The alcohol relapse risk assessment: a scoring system to predict the risk of relapse to any alcohol use after liver transplant","volume":"23","author":"Rodrigue","year":"2013","journal-title":"Prog Transplant"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:26:32Z","timestamp":1760855192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125000522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":151,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1089326125000522"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.06.012","relation":{},"ISSN":["1089-3261"],"issn-type":[{"type":"print","value":"1089-3261"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Approaches to Alcohol-Associated Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}